Board of Trustees of The Leland Stanford Junior University’s BridgeBio Pharma BBIO Stock Holding History

Board of Trustees of The Leland Stanford Junior University’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-331,283	Closed	-$9.09M	–	21
2024 Q4	$9.09M	Hold	331,283	–	–	0.78%	9
2024 Q3	$8.43M	Hold	331,283	–	–	0.72%	7
2024 Q2	$8.39M	Hold	331,283	–	–	0.57%	7
2024 Q1	$10.2M	Hold	331,283	–	–	0.9%	6
2023 Q4	$13.4M	Hold	331,283	–	–	0.87%	9
2023 Q3	$8.74M	Hold	331,283	–	–	0.68%	7
2023 Q2	$5.7M	Hold	331,283	–	–	0.57%	8
2023 Q1	$5.49M	Hold	331,283	–	–	0.51%	10
2022 Q4	$2.52M	Hold	331,283	–	–	0.26%	11
2022 Q3	$3.29M	Hold	331,283	–	–	0.21%	20
2022 Q2	$3.01M	Hold	331,283	–	–	0.2%	14
2022 Q1	$3.36M	Hold	331,283	–	–	0.19%	14
2021 Q4	$5.53M	Hold	331,283	–	–	0.35%	16
2021 Q3	$15.5M	Hold	331,283	–	–	1.16%	11
2021 Q2	$20.2M	Hold	331,283	–	–	1.89%	10
2021 Q1	$20.4M	Buy	+331,283	New	+$21.7M	1.8%	10

Other funds holding BBIO

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Board of Trustees of The Leland Stanford Junior University's BBIO Position: Q1 2025 in Review

Board of Trustees of The Leland Stanford Junior University sold out of BridgeBio Pharma (BBIO) in Q1 2025, closing a stake of 331,283 shares — an estimated $9.09M sold.

Board of Trustees of The Leland Stanford Junior University first reported a position in BBIO in Q1 2021 and held it in 16 quarters. The position peaked at $20.4M in Q1 2021. 304 funds tracked by Wall St. Rank hold BBIO as of Q1 2025.

Board of Trustees of The Leland Stanford Junior University reported no remaining BridgeBio Pharma position as of Q1 2025 after selling out during the quarter.
Board of Trustees of The Leland Stanford Junior University sold 331,283 BridgeBio Pharma shares in Q1 2025, an estimated $9.09M.
Board of Trustees of The Leland Stanford Junior University first reported a position in BridgeBio Pharma in Q1 2021 and held it in 16 quarters.
Board of Trustees of The Leland Stanford Junior University's BridgeBio Pharma position peaked at $20.4M in Q1 2021.
304 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2025.

Based on Board of Trustees of The Leland Stanford Junior University's 13F filing for Q1 2025, filed 15 May 2025.